PROCEPT BioRobotics Corp. to Report Third Quarter 2021 Financial Results on November 4, 2021

Rhea-AI Summary

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) will report its third-quarter 2021 financial results on November 4, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, accessible via phone or webcast. The company specializes in urological surgical robotics, focusing on the AquaBeam Robotic System, which treats benign prostatic hyperplasia (BPH), affecting approximately 40 million men in the U.S. PROCEPT has established a robust clinical foundation with nine studies and over 100 peer-reviewed publications supporting its Aquablation therapy.

Positive

• Upcoming earnings report may reveal promising financial metrics.
• Established clinical evidence, including nine studies and over 100 publications, supports Aquablation therapy.

Negative

• None.

REDWOOD CITY, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- PROCEPT^® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter 2021 after the market close on Thursday, November 4, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (800) 306-0005 for domestic callers or (209) 950-5968 for international callers, using conference ID: 7198987. Live audio of the webcast will be available on the “Investors” section of the company’s website at: https://ir.procept-biorobotics.com. The webcast will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation

PROCEPT is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. PROCEPT has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Gilmartin Group
Matt Bacso, CFA
Matt.bacso@gilmartinir.com

FAQ

When will PROCEPT BioRobotics report its third-quarter financial results?

PROCEPT BioRobotics will report its third-quarter financial results on November 4, 2021, after market close.

What time is the PROCEPT BioRobotics conference call scheduled?

The conference call is scheduled for 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on November 4, 2021.

How can I listen to the PROCEPT BioRobotics conference call?

Investors can listen to the conference call by dialing (800) 306-0005 for domestic calls or (209) 950-5968 for international calls, using conference ID: 7198987.

What is the focus of PROCEPT BioRobotics' AquaBeam Robotic System?

The AquaBeam Robotic System focuses on treating benign prostatic hyperplasia (BPH) in minimally-invasive urologic surgery.

How many clinical studies support Aquablation therapy?

Aquablation therapy is supported by nine clinical studies and over 100 peer-reviewed publications.